![]() A better-ranked stock in the pharma sector is ACADIA Pharmaceuticals Inc. Kite Pharma currently carries a Zacks Rank #3 (Hold). Other studies revolving around axicabtagene ciloleucel are also advancing fast.Īpart from axicabtagene ciloleucel, Kite Pharma is developing additional CAR-based candidates including KITE-585 and KITE-718. Though the efficacy profile of all the three candidates is comparable, axicabtagene ciloleucel is likely set to hit the market first. JUNO and Novartis AG NVS are also developing JCAR017 and CTL019, respectively, utilizing the CAR-T cell technology. There are several other companies working to bring about innovative immuno-oncology treatments to the market. ![]() Immuno-oncology is one of the most actively pursued areas of research today. In July, a regulatory application was also filed in the EU for the given indication with sanction and unveiling also expected next year. The candidate is expected to be approved of and launched in the United States this year. At the second-quarter conference call, the company announced that the FDA has informed that an Advisory Committee meeting will not be required to review the company’s BLA for axicabtagene ciloleucel. We believe that the solid efficacy profile demonstrated by the pivotal ZUMA-1 trial should support the candidate’s approval this year. The Biologics License Application (BLA) filing was based on data from a phase I-II study, ZUMA-1. The candidate is currently under priority review in the United States for treating aggressive non-Hodgkin lymphoma (NHL) with an FDA decision expected on Nov 29. Kite Pharma has been riding on the back of an impressive progress made by axicabtagene ciloleucel.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |